Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO)

Abeona Therapeutics Inc. ( ABEO ) has just reported FY25 earnings. They posted a very impressive GAAP EPS of $1.01, missing expectations by $0.17. But the reality here is that they benefited from a one-time gain via the saleI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an apprecia ...